Volume 10, Issue 5, Pages (May 2012)

Slides:



Advertisements
Similar presentations
IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.
Advertisements

The Origin and Evolution of Mutations in Acute Myeloid Leukemia
Volume 8, Issue 3, Pages (March 2017)
Volume 132, Issue 3, Pages (February 2008)
Virtual Karyotyping Reveals Greater Chromosomal Stability in Neural Cells Derived by Transdifferentiation than Those from Stem Cells  Uri Weissbein, Uri.
Self-Excising Retroviral Vectors Encoding the Cre Recombinase Overcome Cre- Mediated Cellular Toxicity  Daniel P. Silver, David M. Livingston  Molecular.
Targeted, High-Depth, Next-Generation Sequencing of Cancer Genes in Formalin- Fixed, Paraffin-Embedded and Fine-Needle Aspiration Tumor Specimens  Andrew.
Grounded: Transcriptional Pausing in Naive mESCs
Volume 25, Issue 3, Pages (March 2014)
Volume 9, Issue 4, Pages (October 2011)
Volume 18, Issue 5, Pages (May 2016)
Daniel Chi-Hong Lin, Alan D Grossman  Cell 
Jianbin Wang, H. Christina Fan, Barry Behr, Stephen R. Quake  Cell 
Next Generation Sequencing for Clinical Diagnostics-Principles and Application to Targeted Resequencing for Hypertrophic Cardiomyopathy  Karl V. Voelkerding,
Plasmid-Based Materials as Multiplex Quality Controls and Calibrators for Clinical Next- Generation Sequencing Assays  David J. Sims, Robin D. Harrington,
Ming-Tseh Lin, Roy G. Rich, Royce F. Shipley, Michael J
Molecular Diagnosis of Autosomal Dominant Polycystic Kidney Disease Using Next- Generation Sequencing  Adrian Y. Tan, Alber Michaeel, Genyan Liu, Olivier.
Christopher R. Cabanski, Vincent Magrini, Malachi Griffith, Obi L
Volume 11, Issue 2, Pages (August 2012)
Volume 84, Issue 2, Pages (October 2014)
Shiran Bar, Maya Schachter, Talia Eldar-Geva, Nissim Benvenisty 
Volume 29, Issue 1, Pages (April 2014)
Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9
Volume 17, Issue 1, Pages (September 2016)
Optimizing Cancer Genome Sequencing and Analysis
Volume 9, Issue 2, Pages (August 2011)
Volume 9, Issue 4, Pages (October 2011)
Volume 61, Issue 1, Pages (January 2016)
Volume 15, Issue 5, Pages (November 2014)
Comprehensive Diagnostic Testing for Stereocilin
Volume 7, Issue 1, Pages (April 2014)
Volume 13, Issue 1, Pages (July 2013)
Volume 25, Issue 3, Pages (March 2014)
Volume 24, Issue 4, Pages (July 2018)
The Origin and Evolution of Mutations in Acute Myeloid Leukemia
Volume 9, Issue 3, Pages (March 2006)
Volume 150, Issue 6, Pages (September 2012)
Volume 8, Issue 3, Pages (March 2017)
Volume 15, Issue 5, Pages (November 2014)
Volume 25, Issue 24, Pages (December 2015)
Tamar Ratner, Ron Piran, Natasha Jonoska, Ehud Keinan 
Evolution of the Cancer Stem Cell Model
Volume 3, Issue 2, Pages (August 2014)
Beth Elliott, Christine Richardson, Maria Jasin  Molecular Cell 
Shiran Bar, Maya Schachter, Talia Eldar-Geva, Nissim Benvenisty 
Volume 11, Issue 6, Pages (May 2015)
Volume 14, Issue 6, Pages (June 2014)
Volume 25, Issue 6, Pages (November 2018)
Dynamic Regulation of Nucleosome Positioning in the Human Genome
Volume 16, Issue 4, Pages (April 2015)
José E. Mejía, Adrian Willmott, Elaine Levy, William C
Volume 20, Issue 7, Pages (August 2017)
Volume 14, Issue 6, Pages (June 2014)
An AT-Rich Sequence in Human Common Fragile Site FRA16D Causes Fork Stalling and Chromosome Breakage in S. cerevisiae  Haihua Zhang, Catherine H. Freudenreich 
Volume 7, Issue 2, Pages (August 2010)
Volume 3, Issue 3, Pages (September 2008)
Volume 9, Issue 3, Pages (September 2017)
Volume 23, Issue 3, Pages (March 2015)
Volume 6, Issue 4, Pages (July 2013)
Virtual Karyotyping Reveals Greater Chromosomal Stability in Neural Cells Derived by Transdifferentiation than Those from Stem Cells  Uri Weissbein, Uri.
Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling
Volume 16, Issue 2, Pages (February 2015)
Natalay Kouprina, Vladimir Larionov 
Volume 41, Issue 2, Pages (January 2011)
Molecular Therapy - Nucleic Acids
Volume 8, Issue 5, Pages e8 (May 2019)
Exon Skipping in IVD RNA Processing in Isovaleric Acidemia Caused by Point Mutations in the Coding Region of the IVD Gene  Jerry Vockley, Peter K. Rogan,
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania  Erin L. Crowgey,
Meiotic DNA Breaks at the S. pombe Recombination Hot Spot M26
Trisomy Correction in Down Syndrome Induced Pluripotent Stem Cells
Presentation transcript:

Volume 10, Issue 5, Pages 570-582 (May 2012) Background Mutations in Parental Cells Account for Most of the Genetic Heterogeneity of Induced Pluripotent Stem Cells  Margaret A. Young, David E. Larson, Chiao-Wang Sun, Daniel R. George, Li Ding, Christopher A. Miller, Ling Lin, Kevin M. Pawlik, Ken Chen, Xian Fan, Heather Schmidt, Joelle Kalicki-Veizer, Lisa L. Cook, Gary W. Swift, Ryan T. Demeter, Michael C. Wendl, Mark S. Sands, Elaine R. Mardis, Richard K. Wilson, Tim M. Townes, Timothy J. Ley  Cell Stem Cell  Volume 10, Issue 5, Pages 570-582 (May 2012) DOI: 10.1016/j.stem.2012.03.002 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 OSK Lentivirus Insertion Sites for the Three Reprogramming Experiments Insertion sites of the OSK lentivirus for each iPSC clone are indicated on a representation of the 20 mouse chromosomes. Sites of integration were determined by whole-genome sequencing. Each iPSC line had one to five lentiviral insertion sites. The first number next to each insertion site refers to the experiment, and the second refers to the clone. Experiment 1 insertion sites are indicated in green, experiment 2 in red, and experiment 3 in blue. Cell Stem Cell 2012 10, 570-582DOI: (10.1016/j.stem.2012.03.002) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 Numbers of SNVs Identified in Each iPSC Clone (A) Total number of SNVs (including a small fraction of loss of heterozygosity sites) detected in each iPSC clone compared to its parental fibroblasts. Related to Figure S2. (B) Total number of SNVs detected in the coding regions of each iPSC clone compared to its parental fibroblasts, listed in Table S1. Pathway analysis of these SNVs is shown in Table S5. Cell Stem Cell 2012 10, 570-582DOI: (10.1016/j.stem.2012.03.002) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 3 SNVs in iPSC Clones from Experiments 1 and 2 (A) Variant allele frequency plots of all SNVs for each of the iPSC clones from experiments 1 and 2. Two plots are shown for each clone: kernel density (top) and iPSC variant allele frequencies by sequence coverage (bottom). The traditional kernel density estimation (KDE, Experimental Procedures) reveals that each iPSC sample is composed of a single dominant clone, with no apparent subclones. (B) Relationship of the total SNVs detected within each iPSC clone. No shared SNVs were detected in any clone in either experiment. Overlapping regions of the Venn diagram with no numbers contain no SNVs. Cell Stem Cell 2012 10, 570-582DOI: (10.1016/j.stem.2012.03.002) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 4 Shared Genomic Variants Identified in All Four iPSC Clones from Experiment 3 (A) Relationship of the SNVs detected within the coding regions of each iPSC clone. Private and shared mutations were found in all four clones. Overlapping regions of the Venn diagram with no numbers contain no SNVs. Pathway analysis of these SNVs is shown in Table S5. (B) Relationship of the total SNVs (including a small fraction of loss of heterozygosity sites) for each iPSC clone. Overlapping regions of the Venn diagram with no numbers contain no SNVs. Shared SNVs are listed in Table S2 and shared indels are listed in Table S3. (C) An identical SV was identified in all four iPSC clones from experiment 3, spanning ∼130,000 bp on chromosome 6. (D) Detection of shared variants in rare cells from the parental MEF pool. Regions containing the SNVs within the Apaf1 and Sbno2 genes were amplified from the Gusb−/− MEF starting pool from experiment 3, and these amplicons were directly ligated into the pCR2.1 vector. The ligation products were transformed into E. coli; ampicillin-resistant colonies were counted on each 10 cm plate, and pooled. Plasmid DNA was prepared from each pool, and digested with StuI and EcoRI to detect the novel StuI sites generated by the Apaf1 G16A and Sbno2 A3783G variants. Digestion products were separated on 5% polyacrylamide gels, transferred to nitrocellulose, and analyzed by Southern blotting. Expected fragment lengths are indicated below the Southern blots. (∗) indicates the variant-specific digestion products. Quantification data from Illumina sequencing validation is shown in Table S4. Cell Stem Cell 2012 10, 570-582DOI: (10.1016/j.stem.2012.03.002) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 5 Comparison of Shared Versus Private Variant Allele Frequencies for Experiment 3 Left and Center panels: Variant allele frequencies for the shared and private SNVs from the iPSC clones of experiment 3 were plotted. Two plots are shown for each clone: kernel density (top) and iPSC variant allele frequencies by sequence coverage (bottom). The shared SNVs have a single dominant clone with a peak variant allele frequency of ∼50% (left panels). The private SNVs in each clone also have a major peak of variant allele frequency of ∼50%, but the suggestion of a second peak at ∼25% is suggested in clones 1, 2, and 6. The second peak was confirmed only for clone 1 (red arrowhead). Right panels: Validation of variant allele frequencies in iPSC clones. Using whole-genome sequencing data, we selected ten variants with predicted variant allele frequencies (VAFs) of 50% versus 25% for each of the iPSC clones, amplified all variants by PCR, and then performed deep sequencing on the Roche/454-FLX platform. VAFs were plotted for each clone for whole-genome sequencing (x axis, VAF by WGS) versus deep sequencing (y axis, VAF by Roche/454-FLX). For clone 1, the variants with VAFs of ∼25% were statistically confirmed by deep sequencing (p = 0.000045). For the other three clones, the variants with predicted 25% VAF were not confirmed (p > 0.05 for all three). Cell Stem Cell 2012 10, 570-582DOI: (10.1016/j.stem.2012.03.002) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 6 Model for the Acquisition of Genetic Variants during iPSC Reprogramming (A) Model for the genetic variants detected in experiments 1 and 2. Each cell has a unique set of preexisting background mutations, which are “captured” by the expansion and cloning of single cells with reprogramming. Not all cells transduced with the reprogramming vector yield iPSC clones, as suggested by the X's. It is possible that the background mutations in some cells could contribute to reprogramming fitness. (B) Model for the data obtained for experiment 3. Preexisting background mutations in rare cells mark their fitness for reprogramming. Private mutations must be acquired after the shared mutations, and could have arisen at different times: (1) between the time when the shared mutations were acquired and when reprogramming occurred; (2) at the time of reprogramming; or (3) after reprogramming. Some mutations arising after reprogramming may provide a selective advantage for the outgrowth of subclones. Cell Stem Cell 2012 10, 570-582DOI: (10.1016/j.stem.2012.03.002) Copyright © 2012 Elsevier Inc. Terms and Conditions